On Friday, bluebird bio Inc (BLUE) stock saw a decline, ending the day at $0.32 which represents a decrease of $-0.04 or -11.11% from the prior close of $0.36. The stock opened at $0.37 and touched a ...

(NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for ...

On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...

and Bluebird Bio. According to TipRanks, Joseph has an average return of 12.4% and a 56.22% success rate on recommended stocks. In addition to J.P. Morgan, PTC Therapeutics also received a Buy from ...

JPMorgan downgraded Bluebird Bio (BLUE) to Underweight from Neutral without a price target post the Q3 report. Bluebird missed on sales and ...

On Thursday, bluebird bio Inc (BLUE) stock saw a decline, ending the day at $0.36 which represents a decrease of $-0.02 or -5.26% from the prior close of $0.38. The stock opened at $0.37 and touched a ...

JPMorgan Chase & Co. cut shares of bluebird bio (NASDAQ:BLUE – Free Report) from a neutral rating to an underweight rating in ...

bluebird bio (NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of ...

Bluebird Bio's Q3 EPS loss was 31 cents ... per quarter and obtains additional cash resources to extend its runway. JP Morgan downgraded Bluebird after the third-quarter results.

JP Morgan downgraded Bluebird after the third-quarter ... In September, Bluebird bio implemented a restructuring to optimize its cost structure and enable quarterly cash flow break-even in the ...